<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267616</url>
  </required_header>
  <id_info>
    <org_study_id>1603304047</org_study_id>
    <nct_id>NCT02267616</nct_id>
  </id_info>
  <brief_title>Effectiveness of Prolonged Use of IUD/Implant for Contraception</brief_title>
  <acronym>EPIC</acronym>
  <official_title>Effectiveness of Prolonged Use of IUD/Implant for Contraception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Susan Thompson Buffett Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate LNG-IUD and Etonogestrel (ENG) Implant users who are willing to use
      their contraception beyond the end of the FDA-approved duration. ENG Implant users will also
      be offered to participate in an arm of the study that will randomize them to either keeping
      their implant in or having it removed and replaced with a new implant. Participants will be
      followed for up to three years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective cohort study will evaluate 675 LNG-IUD users and 675 Etonogestrel (ENG)
      Implant users who are within 6 months of expiration or beyond the end of the FDA-approved
      duration. Participants will be contacted via telephone and either scheduled to enroll in
      person or be mailed the consent form before participation in the EPIC study. After the signed
      consent form is obtained, participants will also be asked to complete a brief telephone or
      in-person questionnaire on sociodemographic, medical and reproductive history, sexual and
      contraceptive history, history of unintended pregnancy and substance abuse. During the
      informed consent process, implant users will also be offered to participate in an arm of the
      study that will randomize them (if they consent) to either keeping their subdermal implant in
      or have it removed and replaced with a new subdermal implant. The randomized control trial
      subset allows us to compare effectiveness to that of a new implant.

      It also allows us to assess &quot;other contraceptive use&quot; (e.g. condom use) in both groups.

      Participants will also be asked if they are interested in providing a blood sample for
      analysis of etonogestrel assay levels at baseline enrollment and annually. If Follow-up phone
      interviews will occur every 6 months for 36 months beyond the expiration of their method. The
      investigators will attempt to validate all pregnancy outcomes with medical chart reviews.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will evaluate the use of the Etonogestrel Implant or hormonal intrauterine device (IUD) for contraception past the FDA approved duration. The Etonogestrel Implant is currently approved for 3 years of use, and the hormonal IUD is currently approved for 5 years.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>Three years</time_frame>
    <description>Our primary aim is to test the absolute and relative effectiveness of both the LNG-IUD and the ENG implant in a non-inferiority (equivalence) study comparing failure rates of these methods in the 3 years post-FDA approved duration to the failure rates during the first three years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unintended pregnancy rates</measure>
    <time_frame>Three years</time_frame>
    <description>The contraceptive failure (unintended pregnancy) rates for the LNG-IUD and ENG implant users at 12, 24, and 36 months (after FDA-approved duration of use: 5 years for LNG IUD and 3 years for the ENG implant) of the contraceptive method will be compared to those for CHC users.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to contraceptive failure</measure>
    <time_frame>Three years</time_frame>
    <description>we will use Kaplan-Meier curves to describe the distribution of time to contraceptive failure for the LNG-IUD and ENG implant users compared to combined hormonal contraceptive users (control).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomized trial analysis</measure>
    <time_frame>Three years</time_frame>
    <description>An identical analysis will be performed using the &quot;intention-to-treat&quot; principle (i.e. analyze the participant according to the assigned group as determined by randomization).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1350</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Continued Use Implant Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Woman randomly assigned to the continued use of their Etonogestrel Implant will continue to use their Etonogestrel Implant for contraception past FDA-approved duration of 36 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New Implant Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Woman randomly assigned to the new Etonogestrel Implant will have their existing Etonogestrel Implant removed and a new implant placed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational Continued Use Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Women who refuse randomization will have an option of continuing to use their existing Etonogestrel Implant beyond the FDA-approved duration (36 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Etonogestrel Implant</intervention_name>
    <description>Subdermal arm implant</description>
    <arm_group_label>Continued Use Implant Group</arm_group_label>
    <arm_group_label>New Implant Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women age 18-45

          -  Within 6 months of expiration or beyond the end of the FDA-approved duration of use of
             the levonorgestrel intrauterine device (LNG-IUD = 5 years) OR the
             etonogestrel-releasing subdermal implant (ENG implant = 3 years)

          -  Able to consent in English or Spanish.

          -  Not pregnant at the time of enrollment

        Exclusion Criteria:

          -  Have history of female sterilization procedure

          -  Desire for conception in the next 12 months

          -  Not sexually active with a male partner
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey F Peipert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra L Guelker, BA</last_name>
    <phone>317.948.0796</phone>
    <email>sguelker@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa J Muench</last_name>
    <phone>314.362.4317</phone>
    <email>lisajmuench@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra L Guelker, BA</last_name>
      <phone>317-948-0796</phone>
      <email>sguelker@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shannon Barnes, RN MSN</last_name>
      <phone>317.948.7624</phone>
      <email>shanbarn@iupui.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey F Peipert, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa J Muench</last_name>
      <phone>314-362-4317</phone>
      <email>lisajmuench@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Colleen McNicholas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.google.com/webhp?sourceid=chrome-instant&amp;ion=1&amp;espv=2&amp;ie=UTF-8#q=Initial%20national%20priorities%20for%20comparative%20effectiveness%20research%202009</url>
    <description>Institute of Medicine (US). Initial national priorities for comparative effectiveness research. Washington, DC: National Academies Press; 2009.</description>
  </link>
  <link>
    <url>http://www.contraceptivetechnology.org/</url>
    <description>Contraceptive technology. 19th rev. ed. New York, N.Y.: Ardent Media; 2007.</description>
  </link>
  <reference>
    <citation>Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect. 1998 Jan-Feb;30(1):24-9, 46.</citation>
    <PMID>9494812</PMID>
  </reference>
  <reference>
    <citation>Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plann. 2010 Dec;41(4):241-50.</citation>
    <PMID>21465725</PMID>
  </reference>
  <reference>
    <citation>Goodman S, Hendlish SK, Benedict C, Reeves MF, Pera-Floyd M, Foster-Rosales A. Increasing intrauterine contraception use by reducing barriers to post-abortal and interval insertion. Contraception. 2008 Aug;78(2):136-42. doi: 10.1016/j.contraception.2008.03.008. Epub 2008 Jun 18.</citation>
    <PMID>18672115</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologists Committee on Gynecologic Practice; Long-Acting Reversible Contraception Working Group. ACOG Committee Opinion no. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol. 2009 Dec;114(6):1434-8. doi: 10.1097/AOG.0b013e3181c6f965.</citation>
    <PMID>20134301</PMID>
  </reference>
  <reference>
    <citation>Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, Secura G. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011 May;117(5):1105-13. doi: 10.1097/AOG.0b013e31821188ad.</citation>
    <PMID>21508749</PMID>
  </reference>
  <reference>
    <citation>Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23. 2010 Aug;(29):1-44.</citation>
    <PMID>20939159</PMID>
  </reference>
  <reference>
    <citation>Kiriwat O, Patanayindee A, Koetsawang S, Korver T, Bennink HJ. A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracept Reprod Health Care. 1998 Jun;3(2):85-91.</citation>
    <PMID>9710712</PMID>
  </reference>
  <reference>
    <citation>Trussell J. Update on the cost-effectiveness of contraceptives in the United States. Contraception. 2010 Oct;82(4):391. doi: 10.1016/j.contraception.2010.04.008. Epub 2010 May 18.</citation>
    <PMID>20851236</PMID>
  </reference>
  <reference>
    <citation>Trussell J, Lalla AM, Doan QV, Reyes E, Pinto L, Gricar J. Cost effectiveness of contraceptives in the United States. Contraception. 2009 Jan;79(1):5-14. doi: 10.1016/j.contraception.2008.08.003. Epub 2008 Sep 25. Erratum in: Contraception. 2009 Aug;80(2):229-30.</citation>
    <PMID>19041435</PMID>
  </reference>
  <reference>
    <citation>Bahamondes L, Faundes A, Sobreira-Lima B, Lui-Filho JF, Pecci P, Matera S. TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age. Contraception. 2005 Nov;72(5):337-41. Epub 2005 Jul 18.</citation>
    <PMID>16246658</PMID>
  </reference>
  <reference>
    <citation>Mäkäräinen L, van Beek A, Tuomivaara L, Asplund B, Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril. 1998 Apr;69(4):714-21.</citation>
    <PMID>9548163</PMID>
  </reference>
  <reference>
    <citation>Huber J, Wenzl R. Pharmacokinetics of Implanon. An integrated analysis. Contraception. 1998 Dec;58(6 Suppl):85S-90S. Erratum in: Contraception 1999 Feb;59(2):145. Retraction in: Rekers H, Affandi B. Contraception. 2004 Nov;70(5):433.</citation>
    <PMID>10095978</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Jeffrey Peipert</investigator_full_name>
    <investigator_title>The Clarence E. Ehrlich Professor; Chair, Dept of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>Levonorgestrel intrauterine device (LNG IUD)</keyword>
  <keyword>Etonogestrel (ENG) Implant</keyword>
  <keyword>Contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

